NCT03459534 2024-10-28A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsIl-Yang Pharm. Co., Ltd.Phase 3 Recruiting173 enrolled